OBJECTIVES The aim of this study was to analyze whether scar characterization could improve the risk stratification for life-threatening ventricular arrhythmias and sudden cardiac death (SCD).
All patients provided written informed consent to participate. The local ethics committee approved this study.
CONTRAST-ENHANCED CMR. The ce-CMR study was performed either using a 1. 
Scar Characterization for Risk Stratification in CRT Patients A white line is drawn over the surface extending between normal myocardium zones and used as the centerline of a 5-mm radius tube extending beyond the surface (right). This tube enclosed the BZ voxels of the original ce-CMR image that will contribute to the BZ channel mass. BZ ¼ border zone; ce-CMR ¼ contrast-enhanced cardiac magnetic resonance. Values are mean AE SD or n (%). *CRT-D versus CRT-P groups comparison.
6MWT ¼ 6-min walk test; ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; CRT-D ¼ cardiac resynchronization therapy with defibrillator; CRT-P ¼ cardiac resynchronization therapy with pacemaker; GFR ¼ glomerular filtration rate; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-systolic volume; NYHA ¼ New York Heart Association. Table 1 . Follow-up. Six patients (2.7%) were lost to follow-up and were excluded from the analysis. During a median follow-up of 35.5 months (25th to 75th percentiles 12 to 62 months), 25 patients (11.5%) reached the primary endpoint. Five patients (2.3%) died due to SCD; 3 of them had a CRT-P device. Twenty patients (9.2%) received appropriate ICD therapies: 7 received ICD shocks, and 13 were treated with ATP. There were no significant differences in baseline clinical characteristics between patients with or without ICD BZ ¼ border zone; ce-CMR ¼ contrast-enhanced cardiac magnetic resonance; ICD ¼ implantable converter-defibrillator; SCD ¼ sudden cardiac defibrillator.
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MYOCARDIAL SCAR SIZE AND CHARACTERISTICS.
All patients that reached the primary endpoint during follow-up had myocardial scar; in patients without ICD therapy/SCD, the proportion was 52.1%
(p < 0.001). None of the patients without myocardial scar experienced ICD therapies or SCD during followup. Additionally, in the subgroup of patients with scar (n ¼ 125), total scar mass, core mass, and BZ mass were significantly greater in the group with ICD therapies or SCD (Table 3) . Furthermore, the scar was not only more extensive, but also more heterogeneous (higher BZ mass/total scar mass ratio) in those patients with ICD therapies or SCD during follow-up (Table 3) .
Seventy-four (59.2%) patients with myocardial scar exhibited BZ channels within the scar. BZ channels were observed in all patients with ICD therapies or SCD, compared with less than one-half (49%) of patients without ICD therapies or SCD; p < 0.001 ( Figure 3) . Furthermore, the mass of BZ channels was significantly higher in patients reaching the primary endpoint (3.6 AE 3.0 g vs. 1.8 AE 3.4 g; p < 0.001) ( Table 3) .
PREDICTION OF ARRHYTHMIC EVENTS. The causespecific hazard model analysis revealed that male sex was the only clinical baseline characteristic associated with ICD therapy or SCD during follow-up ( 81.3% specificity, and 36.2% positive predictive value.
The second 2-step algorithm, based on scar mass >10 g and BZ mass >5.3 g, predicted the primary endpoint with 100% sensitivity, 79.3% specificity, and 33.3%
positive predictive value ( Figure 5) . Interestingly, the proportion of patients that was classified as low risk by both algorithms was significantly higher in the nonischemic cohort versus the ischemic group.
MYOCARDIAL SCAR AND SECONDARY ENDPOINT.
During follow-up, cardiac death occurred in 23 pa- Cumulative incidence functions for primary endpoint and competitive event depending on scar mass (left) and border zone mass (right), stratified by optimal cutoff points. Abbreviations as in Figure 3 . Tables 2 and 3 .
Abbreviations as in
Scar Characterization for Risk Stratification in CRT Patients -2 0 1 7 : --- predictors of all-cause mortality ( Table 5) . Currently, the decision to implant an ICD is primarily based on the presence of severe LV dysfunction. However, in the present study, none of the multivariate models (Table 4) showed LVEF as an independent predictor of ICD therapies or SCD. This is consistent with prior studies reporting that LVEF lacks both sensitivity and specificity in predicting life-threatening arrhythmias (12) . On the other hand, the results of the present study highlight the potential of ce-CMR-based scar characterization to improve the specificity of risk stratification by identifying patients with CRT indication (thus, with severe LV dysfunction) at low risk of life-threatening TRANSLATIONAL OUTLOOK: A randomized study is required to confirm the usefulness of scar characterization for the identification of CRT candidates that could benefit from adding defibrillator capabilities to the CRT device.
